Immunovaccine signs deal to develop anthrax drug

Immunovaccine Inc. has signed a licensing deal with a Maryland biodefence company to develop and commercialize an anthrax vaccine.  The Halifax vaccine developer announced the agreement with PharmAthene Inc. on Wednesday.

Immunovaccine could receive payments of up to $50 million if the product gets to market. The minimum amount the Halifax biotech firm will get from the United States anthrax developer is $200,000 per year during the development phase. Read the full article here:

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s